FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells

Background OX40 (CD134) is a costimulatory molecule of the tumor necrosis factor receptor superfamily that is currently being investigated as a target for cancer immunotherapy. However, despite promising results in murine tumor models, the clinical efficacy of agonistic αOX40 antibodies in the treat...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Wei, Shahram Salek-Ardakani, Wenjing Yang, Lucia Campos Carrascosa, Adriaan A van Beek, Valeska de Ruiter, Michail Doukas, Timothy S Fisher, Keith Ching, Karlijn van Loon, Patrick P C Boor, Yannick S Rakké, Lisanne Noordam, Pascal Doornebosch, Dirk Grünhagen, Kees Verhoef, Wojciech G Polak, Jan N M IJzermans, Irene Ni, Yik Andy Yeung, Dave Sprengers, Jaap Kwekkeboom
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000816.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e000816.full

Similar Items